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Rivastigmine is a cholinesterase inhibitor which improves cognitive function and is currently being used in patients with mild
to moderate Parkinson’s and Alzheimer’s dementia. This drug can be given orally or topically, as transdermal patch. The latter
form is currently used for most excellent compliance and few side eﬀects. The most common cutaneous side eﬀects are irritative
dermatitis. We report the second case of active sensitization by the rivastigmine-patch in a patient suﬀering from Alzheimer’s
dementia.
1.Introduction
Rivastigmine is a cholinesterase inhibitor which improves
cognitive function and is currently being used in patients
with Parkinson’s and Alzheimer’s dementia. The rivastig-
mine transdermal patch has been approved since July 2007,
and it is now preferred to the oral administration [1].
Safety and tolerability of the rivastigmine were evaluated in
several randomised and multicentre clinical trials. We report
a second case of active rivastigmine-patch sensitization in a
patient suﬀering from Alzheimer’s dementia.
2.CaseReport
In March 2010, a 75-year-old male patient came to our
department of Dermatology presenting on the trunk surface
and proximal upper limbs, erythematosus, and oedematous
patched lesions, sometimes vesicular, bright red, inﬁltrated,
and round in shape (Figure 1).
The patient, suﬀering from Alzheimer’s dementia, was
treated for about a month with rivastigmine 9.5mg/24h
patch. The skin lesions appeared after about 15 days from
the ﬁrst application of the patch; then, he proceeding with
topical corticosteroids, there was only partial skin lesions
improvement. When the rivastigmine transdermal patch
was applied, recurrent lesions in previous application skin
sites are observed.
The rivastigmine transdermal application was stopped
when the patient came to our evaluation, and one month
after skin lesions full remission we started the allergological
study with European standard series and we added sup-
plementary series for rubbers and resins. All the tests were
negative at 72 and 96 hours.
Therefore, rivastigmine patch was performed with posi-
tive result after 48 and 72 hours; in contrast, placebo patch
test with support but without drug showed negative result.
Three months after, we repeated the tests, conﬁrming the
previous results (control test).
Under anesthesiological surveillance, we administered
orally rivastigmine at escalating doses from 1.5mg daily, but
after 72 hours from the ﬁrst administration, the skin lesions
reappeared, an event which could be supposed as an “oral
trigger proof.”
3.Discussion
Rivastigmine is currently used for the symptomatic treat-
mentofParkinson’sandAlzheimer’sdementia.Thisdrugcan
be given orally or topically, as transdermal patch.2 Journal of Allergy
Figure 1: Erythematosus and oedematous patched lesions, bright
red, inﬁltrated, and round in shape on the trunk surface.
Rivastigmine is usually well tolerated [2], and its side
eﬀects are dose dependent, with a frequency of 9.6% in
patients who received 9.5mg/24h rivastigmine patch, of
8.6% in patients who received 17.4mg/24h rivastigmine
patch, and 8.1% in those treated with oral formulation [3].
The transdermal form is a once-daily AD treatment. It
is recommended to have a single application every 24 hours
on clean, dry, hairless, and healthy skin. It should be applied
on the upper or lower back, chest, or upper arms. The patch
should be removed gently and replaced with a new one every
24 hours. It’s recommended not to apply the rivastigmine
patch to the same skin area during the next 2 weeks.
The most frequent side eﬀects reported in the literature
[4] include gastrointestinal disorders followed by central
nervous system disorders and cardiovascular alterations.
Irritant contact dermatitis (90%–98% of cases) are the
cutaneous side eﬀects reported during rivastigmine patch
applications [5]. They appeared within 12 hours from the
application, are characterized by erythematosus, oedema-
tous, and itchy lesions, limited to the area covered by the
patch, which usually disappear after a short period of time
(24 hours), and are characterized by the absence of relapse.
Recently Makris reported the ﬁrst case of rivastigmine’s
transdermal patch hypersensitivity [6].
In our patient, in addition to the characteristic clinical
manifestations “A POIS man,” we describe an hypersensiti-
zation to rivastigmine for three reasons: the occurrence of
an adverse reaction after 15 days from the application of
the transdermal drug, enough time for a possible speciﬁc
immunological sensitization, the simultaneous reactivation
of more injuries during the application, and ﬁnally the
adverse reactions persist beyond the 24 hours reported in
the literature [7]. Moreover, the simultaneous reappearance
of the generalized skin lesions on rivastigmine application
areas after oral treatment showed a condition of speciﬁc
sensitization in our patient.
The allergological study conducted with rivastigmine
positive patch test and the placebo’s negative results con-
ﬁrmed the hypothesis of a speciﬁc hypersensitivity to the
rivastigmine patch in our patient.
In this case, we recommend to interrupt the topical or
systemic therapy, though oral rivastigmine desensitization
was recently reported as eﬀective [6].
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